Last update 21 Nov 2024
CD19/CD22 CAR-T (University of Colorado Denver)
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Autologous CAR-T |
Synonyms CD19 and CD22 Chimeric Antigen Receptor Co-Expressing T Cells (University of Colorado Denver), CD19 and CD22 Chimeric Antigen Receptor Co-Expressing T Cells(University of Colorado Denver), CD19x22 Chimeric Antigen Receptor T-cell Therapy(University of Colorado Denver) |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD22 inhibitors(CD22 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with CD19/CD22 CAR-T (University of Colorado Denver)Phase I Dose Escalation and Preliminary Efficacy Study of Bispecific CD19 and CD22 Chimeric Antigen Receptor Co-Expressing T Cells [CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T)] in Pediatric Patients With Relapsed and/or Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Phase 1/1b Study of Bispecific CD19 and CD22 Chimeric Antigen Receptor Co-Expressing T Cells (CD19x22 CAR T) in Adolescent and Adult Patients With Relapsed and/or Refractory B-Non-Hodgkin's Lymphoma (B-NHL)
100 Clinical Results associated with CD19/CD22 CAR-T (University of Colorado Denver)
Login to view more data
100 Translational Medicine associated with CD19/CD22 CAR-T (University of Colorado Denver)
Login to view more data
100 Patents (Medical) associated with CD19/CD22 CAR-T (University of Colorado Denver)
Login to view more data
100 Deals associated with CD19/CD22 CAR-T (University of Colorado Denver)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Pre B-cell acute lymphoblastic leukemia | Phase 1 | US | 27 Sep 2024 | |
| Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | US | 27 Sep 2024 | |
| B-cell lymphoma refractory | Phase 1 | US | 21 Dec 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free